Company

Our purpose

On a mission for India.

Immuneel is committed to dramatically increase the access to transformational cell-based immunotherapies for cancer patients in India.

India’s own

The “Neel” in Immuneel refers to indigo, a natural blue dye – a colour synonymous with hope and possibility – a dye that is unique and India’s gift to the world.

Immuneel is an Indian company with a global outlook. Our ambition and effort is to make cell therapies affordable in India, and has the potential to enable access globally.

Delivering on our purpose, we are bringing in next-generation cell therapies, harnessing the bioengineered immune cell affordably, revolutionizing cancer care in India and giving hope to our patients.

Visionary leadership

Our leadership team unites us in our purpose to develop and deliver high quality affordable cell therapies through disruptive technologies and to make India a preferred destination for advanced cancer care and treat an under-served patient population.

Our stellar Scientific Advisory Board includes cell and gene therapy inventors and leaders

Our global outlook, development strategy and collaborations are enabled by our luminous scientific advisory board which consists of some of the most prominent names in the world of cell and gene therapy. Their stellar track records in research and its translation to life-saving therapies give assurance and heft to our capabilities. We are advised by the best in the field, to bring the best to India.

Our approach: From bench to bedside

Committed to Make in India with Assured Quality, in everything we do.

Immuneel has built end to end capabilities and processes including cGMP lentiviral vector manufacturing to assure the delivery of high-quality, cost-effective cell therapy in India, maximizing value and efficiency, scientifically.

Scientific approach to Cell Therapy
Regulatory
Development (Targets)
  • Investing in research infrastructure, collaborations, technology platforms.
  • Novelty, safety, affordability, efficacy & efficiency.
Process Development (Platforms)
  • Access to the right manufacturing platforms for cell therapy and lentiviral vectors.
  • Focus on stringent cGMP, a clean room by itself is NOT GMP.
  • Investing in advanced analytics & Quality control experts.
  • Committed to cost effective operations & better cost control across the value chain.
Clinical Trials (Indications)
  • Strategically located: In – hospital manufacturing and access to clinical infrastructure (close to a bone marrow transplant unit).
Manufacturing & Quality
Compliance
Commercial (Delivery and sales)
  • Focussed on making high quality, next generation cell therapies accessible to patients, affordably.
  • Collaborate with the government & hospital chains to deliver to India.
  • Committed to best science and clinical outcomes.

Our multi-product, multi-process facilities are designed to be globally compliant with semi-integrated, semi-automated closed cell manufacturing processes.

We are building a digital paper-less ecosystem that monitors our facilities, instruments and documents, processes, research, learning and compliance in keeping with our commitment to the environment. Our strategically located hub and decentralized model ensures delivery of quality products to our patients, regardless of their location. Our network of advisors and partners coupled with our team’s diverse experience are key enablers in our path to success in delivering our Smart Cell Therapies.

Smart cell therapy Solution
India’s first Integrated Cell Therapy Development & Manufacturing Facility inauguration (from left to right Dr. Renu Swarup, Dr. Arun Anand, Ms. Kiran M Shaw and Dr. Devi Shetty)